Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics

Journal of Clinical Psychiatry

Volumn 65, Issue 8, 2004, Pages 1084-1089

  Lindenmayer, Jean Pierre ^a,d   Eerdekens, Els ^b   Berry, Sally A ^c   Eerdekens, Mariëlle ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^d MANHATTAN PSYCHIATRIC CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 4544230571     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0809     Document Type: Article

References (17)

1. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. For Neoropsychopharmacol 1998;8: 55-66 (Pubitemid 28012861)
2. Rice D. The economic impact of schizophrenia. J Clin Psychiatry 1999;60(suppl 1):4-6 (Pubitemid 29072616)
3. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103-108
4. Ereshefsky L, Saklad SR, Jann MW, et al. Future of depot neuroleptics therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984;45(5, sec 2);50-59 (Pubitemid 14116754)
5. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773 (Pubitemid 24151095)
6. Remington GJ, Adams ME. Depot neuroleptics therapy: clinical considerations. Can J Psychiatry 1995;40:55-S11
7. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201 (Pubitemid 28071427)
8. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651 (Pubitemid 27485972)
9. Quitkin F, Rifkin A, Kane J, et al. Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple-episode schizophrenics. Arch Gen Psychiatry 1978;35:889-892 (Pubitemid 9076802)
10. Kane JM, Eerdekens M, Lindenmayer J-P, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132 (Pubitemid 41070972)
11. Fleischhacker WW, Ferdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month evaluation of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257
12. Kay SR, Fiszbein A, Opler LA, et al. The positive and negative symptom scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-267
13. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale [abstract]. Can J Neurol Sci 1980;7:233
14. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
15. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58:538-546 (Pubitemid 28100274)
16. Hay J. Complications at the site of injection of depot neuroleptics. BMJ 1995;311:421
17. Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry 2001;62:855-859 (Pubitemid 33131171)